trials.go-v.org

Pirtobrutinib With Sonrotoclax and Rituximab for High-Risk Relapsed/Refractory Mantle-Cell Lymphoma Following Covalent BTK-Inhibitor Failure

Mantle Cell Lymphoma (MCL); Relapsed/Refractory Mantle Cell Lymphoma (MCL)

source: ClinicalTrials.govlicence: US NLM public datadatabase: /home/dbs/health.dbmode: tablerecords: 612567 (max_rowid)citation: https://clinicaltrials.gov/

Mantle Cell Lymphoma (MCL); Relapsed/Refractory Mantle Cell Lymphoma (MCL)

Fields

statusNOT_YET_RECRUITING
phase['PHASE2']
study_typeINTERVENTIONAL
countriesChina
sponsorTianjin Medical University Cancer Institute and Hospital
start_date2026-12-08
completion_date2030-12-08
source: ClinicalTrials.govlicence: US NLM public datayear: —id: NCT07944651citation: https://clinicaltrials.gov/study/NCT07944651

JSON